ABCAM Plc Director's Remuneration Disclosure (2683W)
November 05 2014 - 11:17AM
UK Regulatory
TIDMABC
RNS Number : 2683W
ABCAM Plc
05 November 2014
For immediate release 5 November 2014
ABCAM PLC
("Abcam" or "the Company")
Jonathan Milner: Remuneration Disclosure
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the
supply of life science research tools previously announced that
Jonathan Milner stepped down as Chief Executive Officer on 9
September 2014. Jonathan continues to play an active role in the
Company as Deputy Chairman and remains the Company's largest
shareholder.
The information required to be made available pursuant to
section 430(2B) of the Companies Act 2006 is set out below.
-- There was no payment in lieu of notice.
-- As Jonathan was CEO for the financial year June 2014 he
received a bonus in respect of the year under the Abcam plc Annual
Bonus Plan. This comprises a cash element and a Deferred Share
Award. The cash portion was paid at the normal time. The Deferred
Share Award in the form of Nil Cost Options will become exercisable
at the end of the deferral period.
-- The Deferred Share Award in the form of Nil Cost Options
granted in 2013 will subsist in full and become exercisable
following the end of the deferral period.
-- The LTIP 'B' awards granted under the Abcam plc Long Term
Incentive Plan in 2011, 2012 and 2013 will subsist subject to
pro-rating for the period of employment. These will continue to be
subject to performance conditions tested at the normal date.
-- As Jonathan was Chief Executive Officer until 9 September
2014, he will be entitled to an annual bonus under the Abcam plc
Annual Bonus Plan in respect of the period of time in employment
during financial year June 2015. This will be pro-rated for the
period of employment and subject to normal performance conditions.
The cash component will be determined and paid following the end of
the financial year. No Deferred Share Award will be granted.
Further information will be disclosed in the relevant Directors'
Remuneration Report.
For further information please contact:
Abcam + 44 (0) 1223 696 000
Jeff Iliffe, Chief Financial Officer
Numis Securities - Nominated Adviser
& Joint Broker + 44 (0) 20 7260 1000
Michael Meade - Nominated Adviser
James Black - Corporate Broking
Peel Hunt LLP - Joint Broker + 44 (0) 20 7418 8900
Clare Terlouw / Jock Maxwell MacDonald
Brunswick + 44 (0) 20 7404 5959
Justine Mcllroy / Robin Wrench
Notes for editors:
About Abcam plc
Abcam plc is a leading provider of life science research tools
and services, with a wide range of products and expert technical
support, enabling scientists to analyse living cells at the
molecular level and improving the understanding of health and
disease.
Abcam is committed to providing scientists with an extensive
choice of reagents and tools, with the most comprehensive, honest
and up-to-date datasheets and customer reviews, fast delivery and
helpful customer service & technical support. The Company's
catalogue evolves with scientific research trends and is growing
each year to provide customers with products to meet their research
needs. The range now includes primary and secondary antibodies,
proteins, peptides, lysates, biochemicals, immunoassays and other
kits. Abcam also supports its customers by hosting a range of
global scientific events, forums and webinars, providing
opportunities for scientists to get together and present their
work.
Headquartered in Cambridge, UK, Abcam has eight global
subsidiary offices enabling local services, multi-language support
and sells to over 100 countries. The Company was founded in 1998,
and now employs over 740 people. Abcam was admitted to AIM in 2005
(AIM: ABC).
To find out more, please visit www.abcamplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAFSLFMIFLSEFF
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2024 to May 2024
Abcam (LSE:ABC)
Historical Stock Chart
From May 2023 to May 2024
